A phase I/IIa dose escalation study of CHR-3996 in combination with tosedostat in subjects with relapsed refractory multiple myeloma.

Trial Profile

A phase I/IIa dose escalation study of CHR-3996 in combination with tosedostat in subjects with relapsed refractory multiple myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs VRx-3996 (Primary) ; Tosedostat
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MUK-three
  • Most Recent Events

    • 06 Dec 2016 Results (n=20) assessing recommended dose in dose escalation phase of the study was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 21 Nov 2016 According to a CTI BioPharma media release, data from this trial will be presented at the upcoming 58th American Society of Hematology (ASH) Annual Meeting.
    • 10 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top